Ovarian Cancer Clinical Trial

Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube

Summary

This study will evaluate the impact of low dose aspirin on normal fallopian tube fimbriae in women who have surgery to have their fallopian tubes removed. Participants will take a low dose of aspirin for 2 weeks before their surgery. A portion of the removed fallopian tubes will also be collected for future research and routine pathology purposes.

View Full Description

Full Description

Subjects in this study will receive low dose aspirin for 14 days before undergoing surgery to remove fallopian tubes removed to determine whether aspirin decreases inflammation in the fallopian tube. Subjects will also submit blood samples at their initial visit with their oncologist, at the time of surgery and at the pre-operative visit to measure inflammation markers and blood counts. A portion of the subject's fallopian tube will be collected for future research studies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women undergoing gynecologic surgery for presumed benign indications that includes the removal of their fallopian tubes. This may include sterilization procedures, hysterectomy or partial or full adnexectomy.
Eligible women will have fulfilled their childbearing desires
Age > 21 Considered low risk for prevalent fallopian tube cancer (not undergoing risk reducing surgery for a known BRCA mutation or other known hereditary predisposition syndrome, family history of ovarian cancer in a first degree relative.

Exclusion Criteria:

Males
Women who have presumed or known gynecologic cancer
Women less than 21 years of age
Women currently on either regular aspirin therapy, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen or chronic steroidal anti-inflammatory medications.
Women with known bleeding diathesis or bleeding disorder.
Women who do not consent for removal of both fallopian tubes.
Women with a history of gastritis or peptic ulcer disease requiring treatment. (Patients with a history of occasional H1 or H2 blocker use for gastro esophageal reflux disease are NOT excluded).
Women with reported aspirin or NSAID allergy
Women with asthma and/or nasal polyps

Study is for people with:

Ovarian Cancer

Phase:

Early Phase 1

Estimated Enrollment:

18

Study ID:

NCT03771651

Recruitment Status:

Active, not recruiting

Sponsor:

University of Oklahoma

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73117, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Early Phase 1

Estimated Enrollment:

18

Study ID:

NCT03771651

Recruitment Status:

Active, not recruiting

Sponsor:


University of Oklahoma

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.